Fundz

Watching Alzamend Neuro, Inc.? See every signal: funding, hires, M&A, contracts, sentiment.

Book a demoChoose your plan
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →
Back to SEC Filings
Other EventsItem 8.01 · 8-KMEDIUM RiskNegative

Alzamend Neuro, Inc.

Filed: Jul 21, 2026CIK: 0001677077
View on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Dr. Lynne Fahey McGrath, a board director since Alzamend Neuro's June 2021 IPO, passed away on July 20, 2026. This represents a loss of experienced biopharmaceutical sector expertise and strategic guidance for the emerging growth company.

Key Takeaways

Dr. Lynne Fahey McGrath, who served as a director since the company's IPO in June 2021, passed away on July 20, 2026

Chairman William B. Horne emphasized Dr. McGrath's significant contributions to the company's strategy and governance

2 more takeaways

Filing Overview

Form Type8-K
Filing DateJul 21, 2026
Item8.01
CategoryOther Events
CIK0001677077
Risk LevelMEDIUM
SentimentNegative
Signalinformational
Topics
board changeleadership transition

What This Means

Other material events not covered by specific item numbers. The content of the filing determines significance.
View Full Filing on SEC.govBrowse More Filings

Alzamend Neuro, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.